Skip to main content

Table 1 Patient demographics and baseline clinical characteristics

From: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

Parametera

Cohort 1

(n = 23)

Cohort 2

(n = 75)

Cohort 3

(n = 27)

Total

(N = 125)

Age, years

    

 Mean (SD)

65.6 (13.7)

61.8 (13.2)

60.1 (13.9)

62.1 (13.5)

 Median (range)

67 (32–82)

65 (19–83)

62 (28–79)

65 (19–83)

Sex

    

 Female, n (%)

19 (82.6)

47 (62.7)

17 (63.0)

83 (66.4)

 Male, n (%)

4 (17.4)

28 (37.3)

10 (37.0)

42 (33.6)

Immunodeficiency diagnosisb

    

 PID diagnosis, n (%)

10 (43.5)

32 (42.7)

19 (70.4)

61 (48.8)

  CVID

5 (50.0)

24 (75.0)

14 (73.7)

43 (70.5)

  Isolated IG subclass deficiency

0

1 (3.1)

2 (10.5)

3 (4.9)

  IgG2 deficiency

0

1 (3.1)

2 (10.5)

3 (4.9)

  Specific antibody deficiency with normo- or hypogammaglobulinemia

0

1 (3.1)

1 (5.3)

2 (3.3)

  Unclassified antibody deficiency

2 (20.0)

3 (9.4)

0

5 (8.2)

  Combined IgA/IgG subclass deficiency

1 (10.0)

0

0

1 (1.6)

  Other

2 (20.0)

6 (18.8)

2 (10.5)

10 (16.4)

SID associated with, n (%)

13 (56.5)

44 (58.7)

8 (29.6)

65 (52.0)

  Chronic lymphocytic leukemia

3 (23.1)

27 (61.4)

6 (75.0)

36 (55.4)

  Multiple myeloma

2 (15.4)

2 (4.5)

0

4 (6.2)

  Post-allogeneic HSCT

1 (7.7)

0

0

1 (1.5)

  Other

7 (53.8)

15 (34.1)

2 (25.0)

24 (36.9)

  1. an value for each parameter is presented based on available data and percentages are calculated as a proportion of those values
  2. bOne patient had a diagnosis of both PID and SID